This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

A sizable medical device company and a handful of small issuers went public in the first week of March, though a ...

The once-fledgling field of MASH drug developers is now one of the few areas of consistency in the biotech industry. And ...

This was the fourth biotech IPO of 2025, and the company raised around $219 million in its IPO, intended to advance its cystic fibrosis treatments. That is a market dominated Vertex ...

After hitting a record high in 2021, the number of biotech IPOs have fallen to a yearly average in the 20s, with most successful entries in the last few quarters involving companies with mid- to ...

The biotech is developing two candidates ... Another slice of the targeted IPO haul is earmarked for a proof-of-concept trial of F598, Alopexx’s other lead candidate. Sanofi licensed the ...

Sionna Therapeutics, a Waltham biotech targeting cystic fibrosis, raised $219.2 million in an IPO last month, and two other Bay State biotechs — Odyssey of Boston and Alopexx of Cambridge ...

This week, Germany-based Anbio Biotechnology (NNNN) is expected to raise capital during its IPO. "NNNN is seeking US public capital market investment as it aims to commercialize its in vitro ...

The funding can support investment in as many as 60 new life sciences companies, said Sofinnova chairman Antoine Papiernik.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO ...

Septerna stood out from the crowd of biotech IPOs last year due to the lack of clinical data to hand. Now, the data are coming in—and it’s led the biotech to abandon its lead asset.

Belrise Industries aims to raise Rs 2,150 crore, while Paramesu Biotech plans to mop up Rs 600 crore through the public issue.